Silo Pharma Initiates Intranasal Drug-Device Study for PTSD Treatment, Partners with Resyca for IND Submission

Reuters
21 May
Silo Pharma Initiates Intranasal Drug-Device Study for PTSD Treatment, Partners with Resyca for IND Submission

Silo Pharma Inc. has announced a new clinical study in collaboration with Resyca BV, focusing on the drug-device combination for their lead asset, SPC-15. The study aims to collect the final device data and documentation necessary for an Investigational New Drug $(IND.AU)$ submission to the U.S. Food and Drug Administration (FDA) later this year. SPC-15 is designed as an intranasal treatment for post-traumatic stress disorder (PTSD) and utilizes a microchip-based nasal spray system to deliver molecules directly to the brain, bypassing the blood-brain barrier. This approach is intended to increase drug concentration and potentially enhance therapeutic outcomes. Currently, Silo Pharma is also conducting an IND-enabling GLP-compliant toxicology and toxicokinetics study, along with an FDA-requested 7-day safety and toxicology study in large animals.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silo Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9455536-en) on May 21, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10